SEC Filing Summary: Obalon Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. on September 26, 2018. The registrant is an emerging growth company incorporated in Delaware. The filing reports a specific regulatory event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The material event reported is the approval by the U.S. Food and Drug Administration (FDA) of a Premarket Approval Supplement application for the Obalon Touch™ Inflation System. This system is an automated device used to inflate the Obalon Balloon.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the regulatory approval. The primary disclosure is the successful regulatory milestone for the inflation system.
Investor Verification Checklist
- Verify the commercial availability timeline for the Obalon Touch™ Inflation System following FDA approval.
- Confirm the impact of this approval on the company's product roadmap and potential revenue streams.
- Review the attached press release (Exhibit 99.1) for additional details on the approval scope.
- Check subsequent filings for any financial impact resulting from the deployment of the new system.